|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Thiopurine therapy in inflammatory bowel disease patients: Analyses of two 8‐year intercept cohorts显示文摘 | B.Jharap M.L.Seinen N.K.H.de Boer J.R.van Ginkel R.K.Linskens J.C.Kneppelhout C.J.J.Mulder A.A.van Bodegraven | 2010 | Inflamm Bowel Dis2010，，9： | 2 |
| 2 | 鞘氨醇-1-磷酸的定量测定——一种新的竞争性结合方法显示文摘鞘氨醇 1 磷酸 (SPP)是重要的细胞第二信使 ,影响细胞的生长和死亡 .通过培养和收集转染SPP受体 EDG 1的HEK2 93细胞 ,与标记及非标记SPP共孵育 ,利用它们与HEK2 93细胞的竞争性结合 ,测定细胞、血清和组织中SPP含量 .该法无需特殊仪器 ,可以测到皮摩尔水平的低含量 ,批间差异小于 15 % (6次 ) . | 屠振兴 龚燕芳 J.R.van BROCKL YN S. SPIEGEL | 2000 | 生物化学与生物物理进展2000，27，4： | 1 |
| 3 | 肺PET图像的定量分析:挑战和机遇显示文摘数百万人受呼吸系统疾病的影响,导致巨大的全球性健康困扰。由于目前对导致呼吸系统疾病发展和进展的潜在机制认识不足,治疗选择仍然有限。为克服此局限和理解相关分子变化,将无创影像技术如PET和SPECT用于探索生物标志物,其中18F-脱氧葡萄糖(FDG)PET显像的研究最多。由于肺内组织、气体、血液和水的构成比变异,定量分析肺的分子影像数据仍具挑战性。这些成分的比例随着肺部疾病的不同而不同,因此有不同的定量分析方法来显示这种变化,但迄今为止还没有开发出对数据标准化的方法。该文回顾了肺部疾病中18F-FDG PET定量分析方法的数据,聚焦于解释肺内成分变化的方法,解读衍生参数。分析的疾病包括急性呼吸窘迫综合征、慢性阻塞性肺疾病、肺间质性疾病如特发性肺纤维化。基于对既往文献、进行中的研究以及作者间讨论的回顾,作者提出了建议性的注意事项,以协助解读从这些方法及未来研究设计中衍生的参数。 | 陈聪霞(译) 李文婵(译) 郭悦(译) 姚稚明(审校者) Delphine L.Chen Joseph Cheriyan Edwin R.Chilvers Gourab Choudhury Christopher Coello Martin Connell Marie Fisk Ashley M.Groves Roger N.Gunn Beverley F.Holman Brian F.Hutton Sarah Lee William MacNee Divya Mohan David Parr Deepak Subramanian Ruth Tai-Singer Kris Thielemans Edwin J.R.van Beek Laurence Vass Jeremy W.Wellen Ian Wilkinson Frederick J.Wilson | 2019 | 中华核医学与分子影像杂志2019，39，11： | 0 |
| 4 | 以铂类为基础的辅助化疗治疗Ⅰ期子宫浆液乳头状癌(UPSC)的效果显示文摘Objective. To determine the efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC). Methods. A retrospective multi-institu-tional investigation was performed to identify surgically staged patients with Stage I UPSC who were (1) treated after surgery with 3-6 courses of platinum-based chemotherapy without radiation from 1990-2003, and (2) followed for a minimum of 12 months, or until recurrence. Results. Six patients (IA-2, IB-3, IC-1) were treated with carboplatin (AUC 6) or cisplatin (50 mg/m2) alone. One patient recurred to the vagina, was treated with chemo-radiation, and is alive and well at 122 months. One patient recurred to the lung, liver, and brain, and died of disease at 24 months. The remaining 4 patients are alive with no evidence of disease 15-124 months (mean 62 months) after treatment. Two patients (IB-1, IC-1) were treated with cisplatin (50 mg/m2) and cyclophosphamide (1000 mg/m2), and both are alive and well with no evidence of disease 75 and 168 months after treatment. Twenty-one patients (IA-5, IB-13, IC-3) were treated with a combination of carboplatin (AUC 6)-and paclitaxel (135 mg/m2-175 mg/m2). One patient recurred to the vagina after 3 cycles of carboplatin/paclitaxel, and was treated with chemo-radiation. She is now without evidence of disease 10 months after treatment. At present, all 21 patients with Stage I UPSC treated following surgical staging with carboplatin/ paclitaxel chemotherapy are alive and well with no evidence of disease 10-138 months (mean 41 months) after treatment. Conclusion. Combination carboplatin/paclitaxel chemotherapy following surgery is effective in the treatment of Stage I UPSC. | Dietrich III C.S. Modesitt S.C. Depriest P.D. J.R.Van Nagell Jr. 李奎 | 2006 | 世界核心医学期刊文摘(妇产科学分册)2006，0，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员